 |
|
Rochester-led Parkinson's study pays off again, 2 decades later
October 13, 2009Data collected in 1980s points to method to predict course of disease
Parkinson disease progresses more slowly in patients who have higher levels of urate, a chemical that at very high level is associated with gout, scientists have found. While it's unknown whether the high levels actually somehow protect patients or simply serve as a marker of protection, the finding supports the idea that patients and doctors may one day be able to better predict the course of the illness.
The study, led by scientists at Massachusetts General Hospital and the Harvard School of Public Health and including physicians at the University of Rochester Medical Center, was published online in the Archives of Neurology.
The new findings are based on biological samples, primarily blood and cerebrospinal fluid, collected from people with Parkinson disease who participated in a landmark study known as DATATOP, which was conducted two decades ago.
DATATOP, conceived and led by Rochester neurologist Ira Shoulson, M.D., is best known for shifting the landscape of neurology clinical research. Shoulson convinced dozens of investigators around the world to work together, pooling their resources to ask questions about potential new treatments for the disease - big questions that could be answered only with participation by hundreds of people with the disease.
Beginning in 1987, Shoulson and colleagues studied 800 people with Parkinson disease, looking at whether the drug deprenyl (selegiline), vitamin E, or a combination might slow the progression of the disease. The answer was a definitive "no" for vitamin E, while deprenyl provided patients with some relief.
But the scale and scope of the study proved to be useful beyond the specific questions it was designed to answer. The mountain of information collected on the 800 participants over eight years provided one of the great repositories of data about Parkinson disease ever assembled: thousands of blood, urine, and cerebrospinal fluid samples, as well as notes from more than 16,000 physical examinations of patients by doctors and nurses.
The data was central to the new study, which was led by Michael A. Schwarzschild, M.D., Ph.D., of Massachusetts General Hospital, and Alberto Ascherio, M.D. of the Harvard School of Public Health, who have been studying a possible role for urate in protecting patients against the effects of Parkinson disease. They found that the disease progressed more slowly in participants with the highest levels of urate than in people with the lowest levels.
The results mirror those of a study the same team published last year, when they studied data from another previous study, also led by Shoulson, which had looked at the effects of an experimental compound in 806 people who had been recently diagnosed with Parkinson disease. While the compound did not slow the disease, the study itself yielded another mountain of critical data.
With data from two previous studies proving so useful, Shoulson is working on ways to make current studies even more useful down the road. With funding from the National Institute of Neurological Disorders and Stroke, he is continuing to follow 537 of the original 806 people involved in one of the previous studies, monitoring the progression of their disease as well as obtaining blood and tissue samples for further investigation.
"This group comprises the largest living laboratory in the world for the study of the progression of Parkinson disease," said Shoulson.
Shoulson hopes to grow the size of the group by adding participants from other studies to create one large cohort of 1,200 people with Parkinson disease who will be studied closely for five years. Doctors will track the health of participants and will make frequent measurements of several biomarkers, including certain blood proteins and genetic mutations that might affect the course of the disease.
"Why put together a large clinical trial to look at one question, then dissolve the entire structure and start all over again?" asked Shoulson. "Instead, we are taking full advantage of what has been accomplished previously. We are putting to better use the resources, efforts and time not only of scientists but also of the hundreds of patients with Parkinson disease who have been so generous to take part in our studies. Making the most of these resources to improve the lives of patients is what the clinical research enterprise is all about."
Meanwhile, the team led by Schwarzschild is conducting a new study funded by the Michael J. Fox Foundation to determine the safety of using inosine, a nutritional supplement known to raise urate levels, in patients. Until more is known, physicians caution Parkinson patients not to take inosine in an effort to slow the disease. The study is being coordinated by Rochester's Clinical Trials Coordination Center.
University of Rochester Medical Center
The new findings are based on biological samples, primarily blood and cerebrospinal fluid, collected from people with Parkinson disease who participated in a landmark study known as DATATOP, which was conducted two decades ago.
DATATOP, conceived and led by Rochester neurologist Ira Shoulson, M.D., is best known for shifting the landscape of neurology clinical research. Shoulson convinced dozens of investigators around the world to work together, pooling their resources to ask questions about potential new treatments for the disease - big questions that could be answered only with participation by hundreds of people with the disease.
Beginning in 1987, Shoulson and colleagues studied 800 people with Parkinson disease, looking at whether the drug deprenyl (selegiline), vitamin E, or a combination might slow the progression of the disease. The answer was a definitive "no" for vitamin E, while deprenyl provided patients with some relief.
But the scale and scope of the study proved to be useful beyond the specific questions it was designed to answer. The mountain of information collected on the 800 participants over eight years provided one of the great repositories of data about Parkinson disease ever assembled: thousands of blood, urine, and cerebrospinal fluid samples, as well as notes from more than 16,000 physical examinations of patients by doctors and nurses.
The data was central to the new study, which was led by Michael A. Schwarzschild, M.D., Ph.D., of Massachusetts General Hospital, and Alberto Ascherio, M.D. of the Harvard School of Public Health, who have been studying a possible role for urate in protecting patients against the effects of Parkinson disease. They found that the disease progressed more slowly in participants with the highest levels of urate than in people with the lowest levels.
The results mirror those of a study the same team published last year, when they studied data from another previous study, also led by Shoulson, which had looked at the effects of an experimental compound in 806 people who had been recently diagnosed with Parkinson disease. While the compound did not slow the disease, the study itself yielded another mountain of critical data.
With data from two previous studies proving so useful, Shoulson is working on ways to make current studies even more useful down the road. With funding from the National Institute of Neurological Disorders and Stroke, he is continuing to follow 537 of the original 806 people involved in one of the previous studies, monitoring the progression of their disease as well as obtaining blood and tissue samples for further investigation.
"This group comprises the largest living laboratory in the world for the study of the progression of Parkinson disease," said Shoulson.
Shoulson hopes to grow the size of the group by adding participants from other studies to create one large cohort of 1,200 people with Parkinson disease who will be studied closely for five years. Doctors will track the health of participants and will make frequent measurements of several biomarkers, including certain blood proteins and genetic mutations that might affect the course of the disease.
"Why put together a large clinical trial to look at one question, then dissolve the entire structure and start all over again?" asked Shoulson. "Instead, we are taking full advantage of what has been accomplished previously. We are putting to better use the resources, efforts and time not only of scientists but also of the hundreds of patients with Parkinson disease who have been so generous to take part in our studies. Making the most of these resources to improve the lives of patients is what the clinical research enterprise is all about."
Meanwhile, the team led by Schwarzschild is conducting a new study funded by the Michael J. Fox Foundation to determine the safety of using inosine, a nutritional supplement known to raise urate levels, in patients. Until more is known, physicians caution Parkinson patients not to take inosine in an effort to slow the disease. The study is being coordinated by Rochester's Clinical Trials Coordination Center.
University of Rochester Medical Center
Parkinson Disease Current Events and Parkinson Disease News RSSA balancing act in Parkinson's disease: Phosphorylation of alpha-synuclein
Both genetic and pathologic data indicate a role for the neuronal protein alpha-synuclein in Parkinson disease.
Pesticide exposure found to increase risk of Parkinson's disease
The fertile soil of California's Central Valley has long made it famous as one of the nation's prime crop-growing regions. But it's not just the soil that allows for such productivity. Crops like potatoes, dry beans and tomatoes have long been protected from bugs and weeds by the fungicide maneb and the herbicide paraquat.
Immune cells contribute to the development of Parkinson's disease
Parkinson disease is a neurodegenerative disorder that impairs movement, balance, speech, and other functions. It is characterized by the loss of nerves in the brain that produce a substance known as dopamine.
Lessons from yeast: A possible cure for Parkinson's disease?
Parkinson disease (PD) is a debilitating and lethal neurodegenerative disease, for which there is currently no cure. It is caused by the progressive loss of nerve cells that produce the chemical dopamine and is characterized by the accumulation of abnormal aggregates of a protein called alpha-syn in these dopaminergic nerve cells.
New Study Shows that Fetal Cells Transplanted into the Brain to Treat Parkinson's Disease May Not Function Long Term
Neurons grafted into the brain of a patient with Parkinson's disease fourteen years ago have developed Lewy body pathology, the defining pathology for the disease, according to research by Jeffrey H. Kordower, PhD, and associates and published in the April 6 issue of Nature Medicine.
Family study bolsters link between pesticides and Parkinson's
For the first time, the association between Parkinson's disease and exposure to pesticides has been shown in patients with the neurological disorder compared with their unaffected relatives, according to a study in the online open access journal BMC Neurology.
Practice parameters discuss treatment for narcolepsy, other hypersomnias of central origin
Practice parameters published in the December 1 issue of the journal SLEEP serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hypersomnias of central origin, including idiopathic hypersomnia, recurrent hypersomnia and hypersomnia due to medical condition.
PINK1 protects from Parkinson's
Parkinson disease (PD) is a common neurodegenerative disease characterized by the selective loss of midbrain dopaminergic neurons.
Researchers identify protein pathway involved in Parkinson disease development
Scientists have found a novel signaling pathway in cells that is altered by genetic mutations recently identified in Parkinson disease development.
Medical therapy for restless legs syndrome may trigger compulsive gambling
Compulsive gambling with extreme losses — in two cases, greater than $100,000 — by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS).
More Parkinson Disease Current Events and Parkinson Disease News Articles
 |
Parkinson's Disease: A Complete Guide for Patients and Families, Second Edition (A Johns Hopkins Press Health Book) by William J. Weiner MD (Author), Lisa M. Shulman MD (Author), Anthony E. Lang MD FRCP (Author) Recent innovations, including deep brain stimulation and new medications, have significantly improved the lives of people with Parkinson's disease. Nevertheless, medical, emotional, and physical challenges remain. The second edition of this accessible and comprehensive guide provides crucial information for managing this complex condition, including details on the use of medications, diet, exercise, complementary therapies, and surgery. The second edition includes new information about: • The genetic and hereditary pattern of the disease • Medications and uses of established medications • Other approaches to treating the symptoms of Parkinson's • Juvenile-onset Parkinson's disease • Normal pressure hydrocephalus • The effects of... |
 |
Parkinson's Disease: 300 Tips for Making Life Easier by Shelley Peterman Schwarz (Author) Being diagnosed with Parkinson's disease can be distressing, and adjusting to the effects of the disease is often difficult. This indispensable resource for patients, family, friends, and caregivers helps patients rise above PD’s challenges by working smarter, maintaining a positive outlook, and conserving time and energy. Organized by subject, the book covers a wide range of topics, including making the home more accessible; dressing aids and simple clothing adaptations; using technology to improve communication; eating and drinking tips for people with difficulty swallowing; mobility and exercise; managing home health care; cars and driving; leisure and recreational activities; travel; and much more. A resource section at the end of each chapter contains contact information for the... |
 |
Parkinson's Disease for Dummies (Volume 2 of 2) (EasyRead Large Edition) by Michele Tagliati (Author) A diagnosis of Parkinson's disease is a life-altering event. There is no one way to deal with it. Everyone has a unique set of circumstances, and every patient experiences Parkinson's differently. That's why one book on PD can never be all things to all people. Whether you are living with the disease or are a caregiver or friend to someone who is, you will come to rely on a wide variety of high-quality books, manuals, Web sites, resources and tools. You may be surprised by the voracity of your appetite for newer, better, and just plain more information about PD. And since Parkinson's is-for now, at least-a disease that stays with you for life, your information needs may evolve and change over time. This book represents something incredibly important: a place to start. We commend its... |
 |
The Parkinson's Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications by J. Eric Ahlskog M.D. Ph.D. (Author) Nearly one million Americans, including Michael J. Fox and Muhammad Ali, suffer from Parkinson's Disease. Now, a leader in the fight against Parkinson's, Dr. J. Eric Ahlskog of the Mayo Clinic, has written the definitive guide for patients and their families. Dr. Alhskog offers a crystal-clear, nuts-and-bolts approach to the treatment of PD, distilled from over twenty years of experience as a clinician and researcher. His goal is to educate the patient so that they can better team with their doctor to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information: How do I know if I have PD? What kinds of tests can I take? What medications slow the progress of the disease? What if medications... |
 |
Delay the Disease -Exercise and Parkinson's Disease by David Zid (Author), Jackie Russell (Editor), RN (Editor), BSN (Editor), CNOR (Editor), Photography - Joanne Adams (Editor), BFA (Editor), CMI (Editor) David Zid, an ACE, APG certified trainer, has collaborated with orthopedic surgeon, Thomas H. Mallory, M.D., who is afflicted with Parkinson's disease, in the development of a Parkinson's specific fitness program designed to proactively minimize tremors and improve flexibility, stability, balance and strength. Delay the Disease contains colorful photographs of Zid demonstrating each move, as well as recommendations for exercise frequency, modification and how to adjust the workout as one improves. Parkinson's patients participating in Zid's fitness program notice improvement in walking, dressing and maintaining balance. Exercises are divided into categories (wake up call, walking and balance, cardiovascular, strength, facial and vocal, and night-time stretching. |
 |
What Your Doctor May Not Tell You About Parkinson's Disease: A Holistic Program for Optimal Wellness by Jill Marjama-Lyons (Author), Mary J. Shomon (Author) There are over one million people in the U.S. living with Parkinson's disease, a debilitating neurological disorder. Patients can now choose from a variety of increasingly effective treatments, including new drugs, revolutionary surgical techniques, and cutting-edge alternative treatments such as intravenous glutathione therapy. The book covers not only the pros and cons of prescription drug and surgical treatments for Parkinson's, but discusses the latest alternative therapies, including herbal treatments, traditional Chinese medicine, Ayurvedic medicine, diet, exercise, mind-body approaches like Tai Chi, and energy work. With special sections focusing on how patients can deal with persistent problems such as fatigue, depression, and balance problems, and unique chapters that... |
 |
Stop Parkin' And Start Livin': Reversing the Symptoms of Parkinson's Disease by John C. Coleman (Author) Stop Parkin'and Start Livin': Reversing the Symptoms of Parkinson's Disease is an invaluable resource for those diagnosed with Parkinson's Disease. It provides a plan of action and significant information which the reader can use to return to good health and as an adjunct to working with supportive therapists. |
 |
Lappare Foti Root Shampoo with Lavender & Menthol (8oz) by EMPIRE VITAMINS INC FO-TI has been used by Chinese over the years. Many people are taking FO-TI and they have observed that their hair is getting darker. It also helps for faster growth of the hair besides making it less gray.The hair is composed of proteins. The melanin in the hair is in charge for the color of the hair. The amount of melanin that is present is responsible for the various colors of the hair. The darker the hair color, the more the melanin content. As people age, the quantity of the melanin in the hair reduces. This causes the hair to become gray and at some point becomes color white. Having a balance diet and sufficient nutrients can help slow down the graying effect on the hair. FO-TI is a herbal plant that can be useful in preventing the graying of the hair when used in shampoos. |
 |
The First Year---Parkinson's Disease: An Essential Guide for the Newly Diagnosed by Jackie Hunt Christensen (Author), Paul, M.D. Tuite (Foreword) Parkinson’s disease—a chronic disorder that causes a progressive loss of nerve cell function in the part of the brain that controls muscle movement—is an incurable neurological condition with debilitating symptoms. Over 1.5 million Americans are affected, and the numbers continue to grow. From the first moment of her Parkinson’s diagnosis, author Jackie Christensen took charge and educated herself on every aspect of her condition. Now, as a "patient-expert," she guides those newly diagnosed step by step through their first year with Parkinson’s. She provides crucial information about the nature of the disease, treatment options, diet, exercise, charts and tables, social concerns, emotional issues, networking with others, and much more. The First Year—Parkinson’s Disease will... |
 |
Living Well with Parkinson's Disease: What Your Doctor Doesn't Tell You....That You Need to Know by Gretchen Garie (Author), Michael J. Church (Author), Winifred Conkling (Author) A complete guide to Parkinson's from two people with the disease who cofounded a national support and advocacy organization. In Living Well with Parkinson's Disease, Gretchen Garie and Michael J. Church, a couple who both have Parkinson's and live daily with the effects of the disease, thoroughly discuss diagnosis, treatment options, and the emotional consequences of this difficult illness. With a conversational, pragmatic, and personal tone, they offer advice on such topics as: how Parkinson's disease affects relationships the role of diet, supplements, and rest and relaxation strategies for navigating professional life and the maze of the health-care system handling everyday challenges such as buttoning a shirt or rolling over in bed and more! Compassionate and... |
| © 2009 BrightSurf.com |